Martyn Nikk Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -247.59%
- Ebitda -247.59%
- Net Worth -39.26%
- Total Assets -24.20%
About Martyn Nikk Pharma
Martyn Nikk Pharma Private Limited (MNPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 July 2019 (Five years and six months 15 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Raghavendra Mohan, Manmohan Singh, and Vikrama Nand serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24230DL2019PTC352899
-
Company No.
352899
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Jul 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Martyn Nikk Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghavendra Mohan
|
Director | 25-Jun-2022 | Current |
|
Manmohan Singh
|
Director | 20-Mar-2024 | Current |
|
Vikrama Nand
|
Director | 20-Mar-2024 | Current |
Financial Performance of Martyn Nikk Pharma.
Martyn Nikk Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 247.59% decrease in profit. The company's net worth observed a substantial decline by a decrease of 39.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Martyn Nikk Pharma?
In 2023, Martyn Nikk Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Associated Formulations Private LimitedRaghavendra Mohan is a mutual person
-
Pranshul Lifesciences Private LimitedManmohan Singh and Vikrama Nand are mutual person
-
Neoaegis Medicare Private LimitedManmohan Singh and Vikrama Nand are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Martyn Nikk Pharma?
Unlock and access historical data on people associated with Martyn Nikk Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Martyn Nikk Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Martyn Nikk Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
